Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Galand, Claire ^a,b,c   Donnou, Sabrina ^a,b,c   Crozet, Lucile ^a,b,c   Brunet, Séverine ^a,b,c   Touitou, Valérie ^a,b,c   Ouakrim, Hanane ^a,b,c   Fridman, Wolf Herman ^a,b,c   Sautès Fridman, Catherine ^a,b,c   Fisson, Sylvain ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 17 RECEPTOR A CHAIN; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL PROLIFERATION INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIMARY INTRAOCULAR B CELL LYMPHOMA; TH17 CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; B CELL LYMPHOMA; BAGG ALBINO MOUSE; BIOSYNTHESIS; DISEASE COURSE; DRUG EFFECT; EYE TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; EYE NEOPLASMS; FEMALE; INTERLEUKIN-17; INTERLEUKINS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; TH17 CELLS; TUMOR BURDEN; TUMOR MICROENVIRONMENT;

EID: 80052930542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024622     Document Type: Article

References (33)

1. Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, et al. (2007) The non-Hodgkin lymphomas: A review of the epidemiologic literature. Int J Cancer 120: 1-39 doi:10.1002/ijc.22719.
2. Cassoux N, Merle-Beral H, Leblond V, Bodaghi B, Miléa D, et al. (2000) Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 8: 243-250.
3. Touitou V, Daussy C, Bodaghi B, Camelo S, de Kozak Y, et al. (2007) Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 48: 3223-3229 doi:10.1167/iovs.07-0008.
4. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159-2169 doi:10.1056/NEJMoa041869.
5. Yang Z-Z, Novak AJ, Stenson MJ, Witzig TE, Ansell SM, (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646 doi:10.1182/blood-2005-08-3376.
6. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149 doi:10.1182/blood-2009-03-208249.
7. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, et al. (2009) T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787-798 doi:10.1016/j.immuni.2009.09.014.
8. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373 doi:10.1182/blood-2007-11-120998.
9. Ouyang W, Kolls JK, Zheng Y, (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467 doi:10.1016/j.immuni.2008.03.004.
10. van de Veerdonk FL, Gresnigt MS, Kullberg BJ, van der Meer JWM, Joosten LAB, et al. (2009) Th17 responses and host defense against microorganisms: an overview. BMB Rep 42: 776-787.
11. Damsker JM, Hansen AM, Caspi RR, (2010) Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 1183: 211-221 doi:10.1111/j.1749-6632.2009.05133.x.
12. Amadi-Obi A, Yu C-R, Liu X, Mahdi RM, Clarke GL, et al. (2007) TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 13: 711-718 doi:10.1038/nm1585.
13. Jones B, Tite JP, Janeway CA Jr, (1986) Different phenotypic variants of the mouse B cell tumor A20/2J are selected by antigen- and mitogen-triggered cytotoxicity of L3T4-positive, I-A-restricted T cell clones. J Immunol 136: 348-356.
14. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, et al. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 71: 1263-1271 doi:10.1158/0008-5472.CAN-10-2907.
15. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149 doi:10.1182/blood-2009-03-208249.
16. Wainwright DA, Sengupta S, Han Y, Ulasov IV, Lesniak MS, (2010) The presence of IL-17A and T helper 17 cells in experimental mouse brain tumors and human glioma. PLoS ONE 5: e15390 doi:10.1371/journal.pone.0015390.
17. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, et al. (2010) Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 184: 1630-1641 doi:10.4049/jimmunol.0902813.
18. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, et al. (2009) Polarization of tumor-associated neutrophil phenotype by TGF-beta: «N1» versus «N2» TAN. Cancer Cell 16: 183-194 doi:10.1016/j.ccr.2009.06.017.
19. Maniati E, Soper R, Hagemann T, (2010) Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653-5662 doi:10.1038/onc.2010.367.
20. Zou W, Restifo NP, (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10: 248-256 doi:10.1038/nri2742.
21. Yang Z-Z, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM, (2009) Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 69: 5522-5530 doi:10.1158/0008-5472.CAN-09-0266.
22. Chan C-C, Fisson S, Bodaghi B, (2009) The future of primary intraocular lymphoma (retinal lymphoma). Ocul Immunol Inflamm 17: 375-379 doi:10.3109/09273940903434804.
23. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S, (2009) Human Th17 cells: are they different from murine Th17 cells? Eur J Immunol 39: 637-640 doi:10.1002/eji.200839050.
24. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, et al. (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408: 57-63 doi:10.1038/35040504.
25. Tzartos JS, Craner MJ, Friese MA, Jakobsen KB, Newcombe J, et al. (2011) IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am J Pathol 178: 794-802 doi:10.1016/j.ajpath.2010.10.043.
26. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, et al. (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704.
27. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121 doi:10.1182/blood.V99.6.2114.
28. Touitou V, Bodaghi B, de Kozak Y, Lehoang P, Sautès-Fridman C, et al. (2008) Animal models of intraocular lymphomas. Ophthalmic Res 40: 208-211 doi:10.1159/000119878.
29. Pongcharoen S, Niumsup P, Sanguansermsri D, Supalap K, Butkhamchot P, (2006) The Effect of Interleukin-17 on the Proliferation and Invasion of JEG-3 Human Choriocarcinoma Cells. American Journal of Reproductive Immunology 55: 291-300 doi:10.1111/j.1600-0897.2006.00366.x.
30. Numasaki M, Fukushi J-ichi, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627 doi:10.1182/blood-2002-05-1461.
31. Akamatsu N, Yamada Y, Hasegawa H, Makabe K, Asano R, et al. (2007) High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 256: 196-206 doi:10.1016/j.canlet.2007.06.001.
32. Andorsky DJ, Timmerman JM, (2008) Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 8: 1295-1307 doi:10.1517/14712598.8.9.1295.
33. Monteleone G, Caruso R, Fina D, Peluso I, Gioia V, et al. (2006) Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55: 1774-1780 doi:10.1136/gut.2006.093187.